Golidocitinib

A Janus kinase inhibitor used in cancer treatment

Golidocitinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Golidocitinib is a Janus kinase (JAK) inhibitor that is being investigated for its potential use in the treatment of various cancers. It specifically targets the JAK1 enzyme, which plays a crucial role in the signaling pathways that regulate immune function and cell growth.

Mechanism of Action

Golidocitinib functions by selectively inhibiting the activity of the JAK1 enzyme. The JAK family of enzymes, which includes JAK1, JAK2, JAK3, and TYK2, is involved in the signaling pathways of various cytokine receptors. By inhibiting JAK1, golidocitinib disrupts the JAK-STAT signaling pathway, which is often dysregulated in cancer cells, leading to uncontrolled cell proliferation and survival.

Clinical Development

Golidocitinib is currently undergoing clinical trials to evaluate its efficacy and safety in treating different types of cancers, including lymphoma and solid tumors. The drug is being studied both as a monotherapy and in combination with other anticancer agents.

Pharmacokinetics

The pharmacokinetic profile of golidocitinib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.

Potential Side Effects

As with other JAK inhibitors, golidocitinib may cause side effects related to its immunosuppressive action. Common adverse effects observed in clinical trials include neutropenia, anemia, and increased risk of infections. Monitoring of blood counts and liver function tests is recommended during treatment.

Research and Development

Research on golidocitinib is focused on understanding its full therapeutic potential and optimizing its use in combination therapies. Ongoing studies aim to identify biomarkers that predict response to treatment and to explore its effects on the tumor microenvironment.

Related Pages

• Janus kinase inhibitor
• Cancer treatment
• Signal transduction
• Cytokine